



## YORKSHIRE EXPERTS COLLABORATE TO DEVELOP NEW CORONARY TECHNOLOGY

A Leeds-based medical device company is seeking £3m investment to fulfil its ambitious plans to bring the first biodegradable coronary stent to the worldwide market. Arterius Ltd is one of only a handful of companies developing this innovative technology, which is set to significantly cut the cost of heart disease treatment in the UK and across the globe. Coronary stent technology has been developed over the years from the bare metal stent, which has a 30 per cent failure rate, to the most recent invention, the drug eluting stent. The development work is being led by industry experts Kadem Al-Lamee and Alistair Taylor with support from three UK universities. Prototypes will be developed by Professor Phil Coates and his team at The University of Bradford, IRC in Polymer Engineering. The company are hopeful that the patented technology will enter Phase 1 clinical trials by 2014. The pair are currently funding the business from their own resources but are now seeking further capital and are taking part in the Investing in Health programme managed by Grant Thornton.

“The team behind the Investing in Health programme has been invaluable in introducing us to potential investors, both nationally and internationally. They have also helped us shape our business plan so that we can approach investors with a solid proposition”.